Charles Pfizer Net Worth: Who He Was and What Sources Say

Charles Pfizer (1824–1906) was the German-American co-founder of what became one of the world's largest pharmaceutical companies. Based on probate records from his estate, his documented cash holdings at death totaled roughly $2.43 million, and his stake in Charles Pfizer & Company stock was later valued at somewhere between $1.9 million and $2.9 million depending on who was doing the calculating. That puts a conservative floor on his estate at around $4 to $5 million in 1906 dollars, which adjusts to somewhere in the range of $130 million to $160 million in today's money. No single authoritative modern figure exists, and you should be skeptical of any website that gives you a clean, tidy number for a man who died 120 years ago.

Which "Charles Pfizer" does this actually refer to?

This is worth clearing up immediately because searches for "Charles Pfizer net worth" pull up a mix of results: some about the modern Pfizer corporation's market capitalization, some about vague "Pfizer salary" estimates from AI-generated net worth sites, and occasionally references to other members of the Pfizer family. If you came here looking specifically for a figure like Dr Charles Handler net worth, keep in mind that for historical founders the number depends heavily on probate records and valuation disputes. The person this query almost always intends is Karl Christian Friedrich Pfizer, born March 22, 1824, in Ludwigsburg, Germany, who immigrated to the United States and co-founded Charles Pfizer & Company with his cousin Charles F. Erhart in Brooklyn, New York in 1849. Wikipedia’s Pfizer page describes the company as founded in 1849 by Charles Pfizer (1824, 1906) and Charles F. Erhart founded in 1849 by Charles Pfizer and Charles F. Erhart. He died on October 19, 1906. That is the Charles Pfizer.

You might also come across references to Emile Pfizer, Charles Pfizer's youngest son, who was later appointed president of the company. Emile is a distinct figure, and his financial profile would be separate. Some sites that generate automated "net worth" pages for "Pfizer" are simply estimating the company's valuation or producing content that conflates the founder with the corporate brand entirely. Neither of those is useful if you want to know about Charles Pfizer the man.

The honest answer: here's the net worth range and why it's fuzzy

The most credible anchor for Charles Pfizer's personal wealth comes from his probate estate, not from any contemporary wealth ranking or financial disclosure. If you are searching for net worth dr charles stauffer, the key takeaway is that credible figures should trace back to estate and probate evidence rather than modern website estimates. The Immigrant Entrepreneurship biographical record reports that his estate included his Brooklyn home and grounds (which passed to his wife) plus $2,433,628 in cash. His wife received approximately one-third of the estate, with the remainder divided equally among his children. On top of that, a New Jersey appellate case (blank" rel="noopener noreferrer">In Re Estate of Pfizer) shows that Charles Pfizer & Company stock held by the estate was sold on June 29, 1942, for $1,916,410 by the executors, while the Treasury Department argued the correct valuation was $2,915,539 and assessed a tentative deficiency before eventually accepting the executors' figure.

So the known documented assets at the time of death were roughly: $2.43 million in cash, a Brooklyn property of unspecified value, and a Pfizer company stake worth at least $1.9 million in a 1942 sale (meaning the value at his 1906 death would have been different, likely lower since the company grew considerably in the intervening decades). A conservative combined estimate in 1906 dollars lands in the $4 million to $5 million range. Adjusted for inflation to 2026 dollars using CPI-based multipliers of roughly 32x to 35x for that era, that translates to approximately $128 million to $175 million. Some analysts applying different inflation indexes or including property appreciation estimates push the figure toward $200 million, but that involves more assumptions.

How Charles Pfizer actually built his wealth

Charles Pfizer arrived in the United States in the late 1840s with chemistry training and a loan of $2,500 from his father. He and his cousin Charles Erhart set up shop in a rented red brick building in the Williamsburg neighborhood of Brooklyn in 1849, initially producing santonin, an antiparasitic compound used to treat intestinal worms. They presented it in a candy-like cone shape to make it more palatable, which was a clever commercial move. That product worked, and it funded early expansion.

The American Civil War became the company's first major wealth accelerator. The Union Army needed massive quantities of pain medications, preservatives, and chemicals including tartaric acid, cream of tartar, and citric acid. Pfizer & Company was positioned to supply them, and the war years drove rapid revenue growth. By the 1880s the company was one of the largest fine chemicals manufacturers in the United States. Charles Pfizer was not just a founder in name; he ran the business actively and held significant ownership throughout his lifetime, which meant his personal wealth tracked closely with the company's growth trajectory.

After the Civil War boom, the company continued expanding its chemical product lines, and by the 1890s it was producing citric acid from imported Italian citrus at scale. Pfizer also moved into Manhattan with expanded operations. When Charles Pfizer died in 1906, the company had been operating for 57 years and was a substantial industrial enterprise, though the era of blockbuster pharmaceuticals and the company's modern scale still lay decades in the future.

Key financial milestones along the way

1. 1849: Founded Charles Pfizer & Company in Brooklyn with a $2,500 family loan and initial capital from cousin Erhart; first product was santonin presented as a candy cone.
2. 1860s: Civil War supply contracts drove the company's first major revenue surge; demand for tartaric acid, pain medications, and preservatives expanded both production and profits.
3. 1868: Charles Erhart (the co-founder and cousin) died, leaving Charles Pfizer as the dominant controlling partner and consolidating family ownership.
4. 1880s–1890s: Company scaled citric acid production and moved into Manhattan; Charles Pfizer's personal ownership stake grew in real value alongside the business.
5. 1900: The company was incorporated as Charles Pfizer & Company, Inc., formalizing equity structures that would later be documented in probate and estate proceedings.
6. 1906: Charles Pfizer died, triggering estate distribution; $2.43 million cash documented plus Brooklyn real estate and company stock held in trust for heirs.
7. 1942: Estate-held Pfizer stock finally sold by executors for $1.9 million, triggering the tax dispute captured in In Re Estate of Pfizer.

How analysts calculate net worth for historical figures like this

For living celebrities or modern executives, net worth estimates draw on SEC filings, stock disclosures, real estate databases, and salary reporting. For someone who died in 1906, the toolkit is completely different. Analysts rely on probate records (which document what the person owned at death and how it was distributed), contemporary news accounts of estate settlements, business incorporation records showing ownership percentages, and any surviving legal disputes over estate valuation, which are particularly useful because they force parties to put specific dollar figures on assets.

The In Re Estate of Pfizer case is a good example of why legal disputes are actually gold for historical wealth research. The fight between the executors and the Treasury Department over the value of Pfizer company stock produced two concrete valuation figures (the $1.9 million sale price and the Treasury's $2.9 million counter-assertion), and the court's resolution tells you which methodology was accepted. That is far more reliable than any modern site estimating a historical figure's wealth from scratch.

The final step is inflation adjustment. Economists typically use either the CPI (Consumer Price Index) or GDP deflator for this. The CPI approach for 1906 to 2026 produces a multiplier in the range of 32x to 35x. A more aggressive approach using the "economic power" method, which measures what a dollar commanded relative to the broader economy, can push the multiplier much higher, sometimes into the 100x to 200x range, but that methodology is more appropriate for measuring societal influence than personal spending power. Most credible estimates for Charles Pfizer use the CPI approach, which is why you see figures in the $130 million to $175 million range.

Why different sites report wildly different numbers

A lot of the variance you see online comes down to a few specific problems. First, many automated net worth sites are estimating "Pfizer" broadly, meaning they are actually reporting some approximation of the modern Pfizer corporation's market capitalization or revenue, which has nothing to do with what Charles Pfizer personally owned in 1906. Some modern pages still mix up Charles Stauffer, but credible Charles Pfizer net worth work traces back to probate and court valuation of the company stake net worth sites. blank" rel="noopener noreferrer">Sites like PeopleAI and some celebrity wealth aggregators generate salary and net worth estimates for "Pfizer" without distinguishing the founder from the company brand. Those numbers are essentially meaningless for this purpose.

Second, even sites that are genuinely trying to estimate the founder's personal wealth make different choices about which assets to include, which inflation index to apply, and whether to include speculative components like the Brooklyn property's value. A site that includes a high estimate for the real estate plus the Treasury's higher Pfizer stock valuation and applies an economic-power inflation multiplier could plausibly arrive at a figure exceeding $300 million. A more conservative analysis using only documented cash, the executors' accepted stock valuation, and a standard CPI multiplier lands closer to $130 million. Neither is technically wrong; they just reflect different assumptions.

Third, some sources conflate Charles Pfizer with other members of the Pfizer family, particularly Emile Pfizer (his son and later company president), which introduces another layer of confusion. Dr. Charles Procter net worth is often mixed into “Charles Pfizer” search results because many sites publish vague or conflated wealth numbers. If you see a net worth figure attached to a "Charles Pfizer" that references events post-1906, someone has muddled the family timeline.

How to verify this yourself and what to actually trust

If you want to do your own digging, here is where the reliable information actually lives. Start with probate records: the Immigrant Entrepreneurship biographical entry on Charles Pfizer is a well-sourced secondary source that draws on primary genealogical and estate records. For the stock valuation dispute specifically, In Re Estate of Pfizer (New Jersey Superior Court, Appellate Division) is accessible through Justia and legal database mirrors and gives you the actual legal record of how the estate's Pfizer stock was valued and contested. Ancestry genealogical records can help confirm biographical details like birth and death dates if you need to verify you are looking at the right person.

For corporate history context, Pfizer's own 175th anniversary materials and corporate history pages confirm the founding story and family ownership transitions. These are useful for understanding the business trajectory but do not give you personal net worth figures directly. Cross-referencing those corporate milestones with the estate records gives you the most complete picture available.

• Trust probate-derived figures: documented cash and stock valuations from estate proceedings are the most reliable anchors available for a historical figure.
• Treat inflation-adjusted figures as ranges, not precise numbers: the choice of inflation index meaningfully changes the outcome, so any site giving you a single clean number is hiding its assumptions.
• Ignore sites estimating 'Pfizer net worth' that are clearly reporting on the modern corporation's valuation rather than the founder's personal estate.
• Be skeptical of figures that reference post-1906 events as part of Charles Pfizer's personal wealth: he died in 1906, and any assets managed after that date belonged to his estate or heirs.
• For peer comparison context, other historical business-founder net worth profiles (such as those for other notable Charles figures in business history) can help calibrate whether a given estimate seems proportionate to the era and company scale.

The bottom line is that Charles Pfizer was genuinely wealthy by the standards of his era, with a documented estate that would be worth well over $100 million in today's money. He was not a Rockefeller or Carnegie, but he built a significant industrial fortune from an immigrant starting point and a $2,500 loan. The uncertainty in the exact figure is not a failure of research; it is simply the reality of estimating personal wealth for someone who lived before modern financial disclosure requirements. Work from the probate records, be honest about the inflation methodology you are using, and be very clear about which member of the Pfizer family you are actually discussing.